In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Atherosclerotic cardiovascular disease (ASCVD) management often involves lipid-lowering therapies.
• High-intensity statins are standard, but side effects can limit adherence.
• Combination therapy with moderate-intensity statins and ezetimibe offers an alternative approach.

Purpose of the Study:

• To compare the long-term efficacy and safety of moderate-intensity statin plus ezetimibe versus high-intensity statin monotherapy.
• To determine non-inferiority of the combination therapy in patients with ASCVD.

Main Methods:

• A randomized, open-label, non-inferiority trial involving patients with ASCVD.
• Participants received either moderate-intensity statin with ezetimibe or high-intensity statin monotherapy.
• Long-term clinical outcomes and safety were assessed.

Main Results:

• The combination therapy group demonstrated non-inferiority to high-intensity statin monotherapy in preventing major adverse cardiovascular events.
• Both treatment strategies showed comparable long-term safety profiles.
• No significant differences in adverse events were observed between the groups.

Conclusions:

• Moderate-intensity statin plus ezetimibe is a viable and effective alternative to high-intensity statin monotherapy for ASCVD patients.
• This combination therapy offers comparable long-term efficacy and safety.
• Treatment guidelines may consider incorporating this combination strategy.